Savara (NASDAQ:SVRA) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Savara (NASDAQ:SVRA) from a hold rating to a sell rating in a report issued on Sunday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Savara Stock Performance

NASDAQ:SVRA opened at $4.81 on Friday. Savara has a 1-year low of $3.34 and a 1-year high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $988.26 million, a price-to-earnings ratio of -8.29 and a beta of 0.20. The stock has a fifty day simple moving average of $5.38 and a 200 day simple moving average of $5.42.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Sell-side analysts forecast that Savara will post -0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. purchased a new stake in shares of Savara during the first quarter valued at approximately $57,000. Sequoia Financial Advisors LLC purchased a new position in Savara in the 2nd quarter worth $69,000. E Fund Management Co. Ltd. bought a new stake in shares of Savara in the 2nd quarter valued at about $77,000. Inceptionr LLC purchased a new stake in shares of Savara during the first quarter valued at approximately $84,000. Finally, Sanctuary Advisors LLC bought a new stake in Savara in the 2nd quarter worth $87,000. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.